Leerink analyst Joseph Schwartz said Raptor Pharmaceuticals' failure in a pediatric NASH Phase 2 trial was not a huge surprise, noting that he'd previously attributed only a 30% probability of success to the program. Schwartz believes Raptor's share price following its pullback attributes little, if any, value to the company's pipeline and its recent Quinsair acquisition and recommends using today's weakness as a buying opportunity. The analyst removed the NASH program from his model and lowered his price target on Raptor shares accordingly to $17 from $20, but reiterates an Outperform rating on the stock, which is down about 38% to $7.48 in morning trading.